Abstract
Tumor cells alter their metabolism by a wide array of mechanisms to promote growth and proliferation. Dysregulated expression and/or somatic mutations of key components of the glycolytic pathway/TCA cycle as well as other metabolic pathways allow tumor cells to improve their ability to survive harsh conditions such as hypoxia and the presence of reactive oxygen species, as well as the ability to obtain nutrients to increase lipids, protein, and nucleic acids biogenesis. Approximately 95% of the human protein encoding genes undergo alternative splicing (AS), a regulated process of gene expression that greatly diversifies the proteome by creating multiple proteins from a single gene. In recent years, a growing body of evidence suggests that unbalanced AS, the formation of certain pro-tumorigenic isoforms and the reduction of anti-tumorigenic isoforms, is implicated in a variety of cancers. It is becoming increasingly clear that cancer-associated AS contributes to increased growth and proliferation, partially due to effects on metabolic reprogramming. Here, we summarize the known roles of AS in regulating cancer metabolism. We present evidence supporting the idea that AS, in many types of cancer, acts as a molecular switch that alters metabolism to drive tumorigenesis. We propose that the elucidation of misregulated AS and its downstream effects on cancer metabolism emphasizes the need for new therapeutic approaches aiming to modulate the splicing machinery to selectively target cancer cells.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Adesso L, Calabretta S, Barbagallo F et al (2012) Gemcitabine triggers a pro-survival response in pancreatic cancer cells through activation of the MNK2/eIF4E pathway. Oncogene 32:2848–2857. doi:10.1038/onc.2012.306
Altman BJ, Stine ZE, Dang CV (2016) From Krebs to clinic: glutamine metabolism to cancer therapy. Nat Rev Cancer 16:619–634. doi:10.1038/nrc.2016.71
Anastasiou D, Poulogiannis G, Asara JM et al (2011) Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science 334:1278–1283. doi:10.1126/science.1211485
Anastasiou D, Yu Y, Israelsen WJ et al (2012) Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. Nat Chem Biol 8:839–847. doi:10.1038/nchembio.1060
Anczuków O, Rosenberg AZ, Akerman M et al (2012) The splicing factor SRSF1 regulates apoptosis and proliferation to promote mammary epithelial cell transformation. Nat Struct Mol Biol 19:220–228. doi:10.1038/nsmb.2207
Araki S, Dairiki R, Nakayama Y et al (2015) Inhibitors of CLK protein kinases suppress cell growth and induce apoptosis by modulating pre-mRNA splicing. PLoS ONE 10:e0116929. doi:10.1371/journal.pone.0116929
Asipu A, Hayward BE, O’Reilly J, Bonthron DT (2003) Properties of normal and mutant recombinant human ketohexokinases and implications for the pathogenesis of essential fructosuria. Diabetes 52:2426–2432. doi:10.2337/diabetes.52.9.2426
Babic I, Anderson ES, Tanaka K et al (2013) EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancer. Cell Metab 17:1000–1008. doi:10.1016/j.cmet.2013.04.013
Baitei EY, Zou M, Al-Mohanna F et al (2009) Aberrant BRAF splicing as an alternative mechanism for oncogenic B-Raf activation in thyroid carcinoma. J Pathol 217:707–715. doi:10.1002/path.2496
Ben-Hur V, Denichenko P, Siegfried Z et al (2013) S6K1 alternative splicing modulates its oncogenic activity and regulates mTORC1. Cell Rep 3:103–115. doi:10.1016/j.celrep.2012.11.020
Bennett CF, Baker BF, Pham N et al (2017) Pharmacology of antisense drugs. Annu Rev Pharmacol Toxicol 5715:1–25. doi:10.1146/annurev-pharmtox-010716-104846
Bienz M, Clevers H (2000) Linking colorectal cancer to Wnt signaling. Cell 103:311–320. doi:10.1016/S0092-8674(00)00122-7
Blaustein M, Pelisch F, Tanos T et al (2005) Concerted regulation of nuclear and cytoplasmic activities of SR proteins by AKT. Nat Struct Mol Biol 12:1037–1044. doi:10.1038/nsmb1020
Bluemlein K, Grüning N-M, Feichtinger RG et al (2011) No evidence for a shift in pyruvate kinase PKM1 to PKM2 expression during tumorigenesis. Oncotarget 2:393–400. doi:10.18632/oncotarget.278
Bonnal S, Vigevani L, Valcárcel J (2012) The spliceosome as a target of novel antitumour drugs. Nat Rev Drug Discov 11:847–859. doi:10.1038/nrd3823
Bos R, van Der Hoeven JJM, van Der Wall E et al (2002) Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 20:379–387. doi:10.1200/jco.2002.20.2.379
Bunn HF, Higgins PJ (1981) Reaction of monosaccharides with proteins: possible evolutionary significance. Science 213:222–224. doi:10.1126/science.12192669
Burt BM, Humm JL, Kooby DA et al (2001) Using positron emission tomography with [(18)F]FDG to predict tumor behavior in experimental colorectal cancer. Neoplasia 3:189–195. doi:10.1038/sj/neo/7900147
Calabretta S, Bielli P, Passacantilli I et al (2015) Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine resistance in pancreatic cancer cells. Oncogene 35:1–9. doi:10.1038/onc.2015.270
Cantor JR, Sabatini DM (2012) Cancer cell metabolism: one hallmark, many faces. Cancer Discov 2:881–898. doi:10.1158/2159-8290.CD-12-0345
Cartegni L, Chew SL, Krainer AR (2002) Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat Rev Genet 3:285–298. doi:10.1038/nrg775
Cassago A, Ferreira AP, Ferreira IM et al (2012) Mitochondrial localization and structure-based phosphate activation mechanism of glutaminase C with implications for cancer metabolism. Proc Natl Acad Sci 109:1092–1097. doi:10.1073/pnas.1112495109
Chaneton B, Hillmann P, Zheng L et al (2012) Serine is a natural ligand and allosteric activator of pyruvate kinase M2. Nature 491:458–462. doi:10.1038/nature11540
Chen M, David CJ, Manley JL (2012) Concentration-dependent control of pyruvate kinase M mutually exclusive splicing by hnRNP proteins. Nat Struct Mol Biol 19:346–354. doi:10.1038/nsmb.2219
Chen L, Kostadima M, Martens JHA et al (2014) Transcriptional diversity during lineage commitment of human blood progenitors. Science 345:1251033. doi:10.1126/science.1251033
Chen W, Wang Y-Y, Zhao A et al (2016) Enhanced fructose utilization mediated by SLC2A5 is a unique metabolic feature of acute myeloid leukemia with therapeutic potential. Cancer Cell 30:779–791. doi:10.1016/j.ccell.2016.09.006
Cheong H, Lu C, Lindsten T, Thompson CB (2012) Therapeutic targets in cancer cell metabolism and autophagy. Nat Biotechnol 30:671–678. doi:10.1038/nbt.2285
Christofk HR, Vander Heiden MG, Harris MH et al (2008a) The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452:230–233. doi:10.1038/nature06734
Christofk HR, Vander Heiden MG, Wu N et al (2008b) Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 452:181–186. doi:10.1038/nature06667
Cohen-Eliav M, Golan-Gerstl R, Siegfried Z et al (2013) The splicing factor SRSF6 is amplified and is an oncoprotein in lung and colon cancers. J Pathol 229:630–639. doi:10.1002/path.4129
Colwill K, Pawson T, Andrews B et al (1996) The Clk/Sty protein kinase phosphorylates SR splicing factors and regulates their intranuclear distribution. EMBO J 15:265–275
Cortes-Cros M, Hemmerlin C, Ferretti S et al (2013) M2 isoform of pyruvate kinase is dispensable for tumor maintenance and growth. Proc Natl Acad Sci 110:489–494. doi:10.1073/pnas.1212780110
Danan-Gotthold M, Golan-Gerstl R, Eisenberg E et al (2015) Identification of recurrent regulated alternative splicing events across human solid tumors. Nucleic Acids Res 43:5130–5144. doi:10.1093/nar/gkv210
Das S, Anczuków O, Akerman M, Krainer AR (2012) Oncogenic splicing factor SRSF1 is a critical transcriptional target of MYC. Cell Rep 1:110–117. doi:10.1016/j.celrep.2011.12.001
David CJ, Chen M, Assanah M et al (2010) HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 463:364–368. doi:10.1038/nature08697
DeBerardinis RJ, Mancuso A, Daikhin E et al (2007) Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. PNAS 104:19345–19350. doi:10.1073/pnas.0709747104
Diggle CP, Shires M, Leitch D et al (2009) Ketohexokinase: expression and localization of the principal fructose-metabolizing enzyme. J Hist Cyt 57:763–774. doi:10.1369/jhc.2009.953190
Dowling JJ (2016) Eteplirsen therapy for Duchenne muscular dystrophy: skipping to the front of the line. Nat Publ Gr 12:675–676. doi:10.1038/nrneurol.2016.180
Düvel K, Yecies JL, Menon S et al (2010) Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell 39:171–183. doi:10.1016/j.molcel.2010.06.022
Dvinge H, Bradley RK (2015) Widespread intron retention diversifies most cancer transcriptomes. Genome Med 7:45. doi:10.1186/s13073-015-0168-9
Dvinge H, Kim E, Abdel-Wahab O, Bradley RK (2016) RNA splicing factors as oncoproteins and tumour suppressors. Nat Rev Cancer 16:413–430. doi:10.1038/nrc.2016.51
Elgadi KM, Meguid RA, Qian M et al (1999) Cloning and analysis of unique human glutaminase isoforms generated by tissue-specific alternative splicing. Physiol Genomics 1:51–62 (pii:1/2/51)
Elkon R, Drost J, van Haaften G et al (2012) E2F mediates enhanced alternative polyadenylation in proliferation. Genome Biol 13:R59. doi:10.1186/gb-2012-13-7-r59
Felig P, Wahren J, Räf L (1973) Evidence of inter-organ amino-acid transport by blood cells in humans. Proc Natl Acad Sci 70:1775–1779. doi:10.1073/pnas.70.6.1775
Finkel RS, Chiriboga CA, Vajsar J et al (2016) Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet 6736:2–11. doi:10.1016/S0140-6736(16)31408-8
Fischer D-C, Noack K, Runnebaum I et al (2004) Expression of splicing factors in human ovarian cancer. Oncol Rep 11:1085–1090. doi:10.3892/or.11.5.1085
Gatenby RA, Gillies RJ (2004) Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4:891–899. doi:10.1038/nrc1478
Ghigna C, Giordano S, Shen H et al (2005) Cell motility is controlled by SF2/ASF through alternative splicing of the Ron protooncogene. Mol Cell 20:881–890. doi:10.1016/j.molcel.2005.10.026
Ghigna C, De Toledo M, Bonomi S et al (2014) Pro-metastatic splicing of Ron proto-oncogene mRNA can be reversed: therapeutic potential of bifunctional oligonucleotides and indole derivatives. RNA Biol 7:495–503. doi:10.4161/rna.7.4.12744
Ghosh G, Adams JA (2011) Phosphorylation mechanism and structure of serine-arginine protein kinases. FEBS J 278:587–597. doi:10.1111/j.1742-4658.2010.07992.x
Golan-Gerstl R, Cohen M, Shilo A et al (2011) Splicing factor hnRNP A2/B1 regulates tumor suppressor gene splicing and is an oncogenic driver in glioblastoma. Cancer Res 71:4464–4472. doi:10.1158/0008-5472.CAN-10-4410
Granados-Riveron JT, Aquino-Jarquin G (2016) The complexity of the translation ability of circRNAs. Biochim Biophys Acta Gene Regul Mech 1859:1245–1251. doi:10.1016/j.bbagrm.2016.07.009
Graubert TA, Shen D, Ding L et al (2011) Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet 44:53–57. doi:10.1038/ng.1031
Hagiwara M (2005) Alternative splicing: a new drug target of the post-genome era. Biochim Biophys Acta Proteins Proteomics 1754:324–331. doi:10.1016/j.bbapap.2005.09.010
Hagiwara A, Cornu M, Cybulski N et al (2012) Hepatic mTORC2 activates glycolysis and lipogenesis through Akt, glucokinase, and SREBP1c. Cell Metab 15:725–738. doi:10.1016/j.cmet.2012.03.015
Hagopian JC, Ma CT, Meade BR et al (2008) Adaptable molecular interactions guide phosphorylation of the SR protein ASF/SF2 by SRPK1. J Mol Biol 382:894–909. doi:10.1016/j.jmb.2008.07.055
Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70. doi:10.1007/s00262-010-0968-0
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674. doi:10.1016/j.cell.2011.02.013
Hansen TB, Jensen TI, Clausen BH et al (2013) Natural RNA circles function as efficient microRNA sponges. Nature 495:384–388. doi:10.1038/nature11993
Hay N (2016) Reprogramming glucose metabolism in cancer: can it be exploited for cancer therapy? Nat Rev Cancer 16:635–649. doi:10.1038/nrc.2016.77
Hayward BE, Bonthron DT (1998) Structure and alternative splicing of the ketohexokinase gene. Eur J Biochem 257:85–91. doi:10.1046/j.1432-1327.1998.2570085.x
He X (2004) Alternative splicing of the multidrug resistance protein 1/ATP binding cassette transporter subfamily gene in ovarian cancer creates functional splice variants and is associated with increased expression of the splicing factors PTB and SRp20. Clin Cancer Res 10:4652–4660. doi:10.1158/1078-0432.CCR-03-0439
Hensley CT, Wasti AT, DeBerardinis RJ (2013) Glutamine and cancer: cell biology, physiology, and clinical opportunities. J Clin Invest 123:3678–3684. doi:10.1172/JCI69600
Higashi T, Saga T, Nakamoto Y et al (2002) Relationship between retention index in dual-phase (18)F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. J Nucl Med 43:173–180
Hirschi B, Kolligs FT (2013) Alternative splicing of BRAF transcripts and characterization of C-terminally truncated B-Raf isoforms in colorectal cancer. Int J Cancer 133:590–596. doi:10.1002/ijc.28061
Hsu TY-T, Simon LM, Neill NJ et al (2015) The spliceosome is a therapeutic vulnerability in MYC-driven cancer. Nature 525:384–388. doi:10.1038/nature14985
Huang Y, Gattoni R, Stévenin J, Steitz JA (2003) SR splicing factors serve as adapter proteins for TAP-dependent mRNA export. Mol Cell 11:837–843. doi:10.1016/S1097-2765(03)00089-3
Ishimoto T, Lanaspa MA, Le MT et al (2012) Opposing effects of fructokinase C and A isoforms on fructose-induced metabolic syndrome in mice. Proc Natl Acad Sci 109:4320–4325. doi:10.1073/pnas.1119908109
Israelsen WJ, Vander Heiden MG (2015) Pyruvate kinase: function, regulation and role in cancer. Semin Cell Dev Biol 43:43–51. doi:10.1016/j.semcdb.2015.08.004
Israelsen WJ, Dayton TL, Davidson SM et al (2013) PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells. Cell 155:397–409. doi:10.1016/j.cell.2013.09.025
Jang SW, Liu X, Fu H et al (2009) Interaction of Akt-phosphorylated SRPK2 with 14-3-3 mediates cell cycle and cell death in neurons. J Biol Chem 284:24512–24525. doi:10.1074/jbc.M109.026237
Jia R, Li C, McCoy JP et al (2010) SRp20 is a proto-oncogene critical for cell proliferation and tumor induction and maintenance. Int J Biol Sci 6:806–826. doi:10.7150/ijbs.6.806
Jiang K, Patel NA, Watson JE et al (2009) Akt2 regulation of Cdc2-like kinases (Clk/Sty), serine/arginine-rich (SR) protein phosphorylation, and insulin-induced alternative splicing of PKCβII messenger ribonucleic acid. Endocrinology 150:2087–2097. doi:10.1210/en.2008-0818
Jung H, Lee D, Lee J et al (2015) Intron retention is a widespread mechanism of tumor-suppressor inactivation. Nat Genet 47:1242–1248. doi:10.1038/ng.3414
Jurica MS, Mesecar A, Heath PJ et al (1998) The allosteric regulation of pyruvate kinase by fructose-1,6-bisphosphate. Structure 6:195–210. doi:10.1016/S0969-2126(98)00021-5
Kaida D, Motoyoshi H, Tashiro E et al (2007) Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA. Nat Chem Biol 3:576–583. doi:10.1038/nchembio.2007.18
Karni R, de Stanchina E, Lowe SW et al (2007) The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol Biol 14:185–193. doi:10.1038/nsmb1209
Karni R, Hippo Y, Lowe SW, Krainer AR (2008) The splicing-factor oncoprotein SF2/ASF activates mTORC1. Proc Natl Acad Sci 105:15323–15327. doi:10.1073/pnas.0801376105
Kim E, Ilagan JO, Liang Y et al (2015) SRSF2 mutations contribute to myelodysplasia by mutant-specific effects on exon recognition. Cancer Cell 27:617–630. doi:10.1016/j.ccell.2015.04.006
Koh CM, Bezzi M, Low DHP et al (2015) MYC regulates the core pre-mRNA splicing machinery as an essential step in lymphomagenesis. Nature 523:96–100. doi:10.1038/nature14351
Kole R, Krainer AR, Altman S (2012) RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov 11:125–140. doi:10.1038/nrd3625
Lee J-H, Gao CF, Lee CC et al (2006) An alternatively spliced form of Met receptor is tumorigenic. Exp Mol Med 38:565–573. doi:10.1038/emm.2006.66
Lee SC-W, Dvinge H, Kim E et al (2016) Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins. Nat Med 22:672–678. doi:10.1038/nm.4097
LeFave CV, Squatrito M, Vorlova S et al (2011) Splicing factor hnRNPH drives an oncogenic splicing switch in gliomas. EMBO J 30:4084–4097. doi:10.1038/emboj.2011.259
Legnini I, Di Timoteo G, Rossi F et al (2017) Circ-ZNF609 is a circular RNA that can be translated and functions in myogenesis. Mol Cell. doi:10.1016/j.molcel.2017.02.017
Li Y, Zheng Q, Bao C et al (2015a) Circular RNA is enriched and stable in exosomes: a promising biomarker for cancer diagnosis. Cell Res 25:981–984. doi:10.1038/cr.2015.82
Li Z, Huang C, Bao C et al (2015b) Exon-intron circular RNAs regulate transcription in the nucleus. Nat Struct Mol Biol 22:256–264. doi:10.1038/nsmb.2959
Li X, Qian X, Peng L-X et al (2016) A splicing switch from ketohexokinase-C to ketohexokinase-A drives hepatocellular carcinoma formation. Nat Cell Biol 18:561–571. doi:10.1038/ncb3338
Lim JS, Mietus-Snyder M, Valente A et al (2010) The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat Rev Gastroenterol Hepatol 7:251–264. doi:10.1038/nrgastro.2010.41
Lin CY, Lovén J, Rahl PB et al (2012) Transcriptional amplification in tumor cells with elevated c-Myc. Cell 151:56–67. doi:10.1016/j.cell.2012.08.026
Liu HX, Cartegni L, Zhang MQ, Krainer AR (2001) A mechanism for exon skipping caused by nonsense or missense mutations in BRCA1 and other genes. Nat Genet 27:55–58. doi:10.1038/83762
Luo W, Hu H, Chang R et al (2011) Pyruvate kinase M2 Is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell 145:732–744. doi:10.1016/j.cell.2011.03.054
Ma XM, Blenis J (2009) Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 10:307–318. doi:10.1038/nrm2672
Maimon A, Mogilevsky M, Shilo A et al (2014) Mnk2 alternative splicing modulates the p38-MAPK pathway and impacts Ras-induced transformation. Cell Rep 7:501–513. doi:10.1016/j.celrep.2014.03.041
Malakar P, Shilo A, Mogilevsky A et al (2017) Long noncoding RNA MALAT1 promotes hepatocellular carcinoma development by SRSF1 upregulation and mTOR activation. Cancer Res 77:1155–1167. doi:10.1158/0008-5472.CAN-16-1508
Malcovati L, Karimi M, Papaemmanuil E et al (2015) SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. Blood 126:233–241. doi:10.1182/blood-2015-03-633537
Masamha CP, Xia Z, Yang J et al (2014) CFIm25 links alternative polyadenylation to glioblastoma tumour suppression. Nature 509:412–416. doi:10.1038/nature13261
Masamha CP, Xia Z, Peart N et al (2016) CFIm25 regulates glutaminase alternative terminal exon definition to modulate miR-23 function. RNA 22:830–838. doi:10.1261/rna.055939.116
Maslon MM, Heras SR, Bellora N et al (2014) The translational landscape of the splicing factor SRSF1 and its role in mitosis. Elife 3:e02028. doi:10.7554/eLife.02028
Matter N, Herrlich P, König H (2002) Signal-dependent regulation of splicing via phosphorylation of Sam68. Nature 420:691–695. doi:10.1038/nature01153
Mayeda A, Krainer AR (1992) Regulation of alternative pre-mRNA splicing by hnRNP A1 and splicing factor SF2. Cell 68:365–375. doi:10.1016/0092-8674(92)90477-T
Mazoyer S, Puget N, Perrin-Vidoz L et al (1998) A BRCA1 nonsense mutation causes exon skipping. Am J Hum Genet 62:713–715. doi:10.1086/301768
Michlewski G, Sanford JR, Cáceres JF (2008) The splicing factor SF2/ASF regulates translation initiation by enhancing phosphorylation of 4E-BP1. Mol Cell 30:179–189. doi:10.1016/j.molcel.2008.03.013
Mirtschink P, Krishnan J, Grimm F et al (2015) HIF-driven SF3B1 induces KHK-C to enforce fructolysis and heart disease. Nature 522:444–449. doi:10.1038/nature14508
Moreadith RW, Lehninger AL (1984) The pathways of glutamate and glutamine oxidation by tumor cell mitochondria. Role of mitochondrial NAD(P)+-dependent malic enzyme. J Biol Chem 259:6215–6221
Murakami T, Nishiyama T, Shirotani T et al (1992) Identification of two enhancer elements in the gene encoding the type 1 glucose transporter from the mouse which are responsive to serum, growth factor, and oncogenes. J Biol Chem 267:9300–9306
Nakajima H, Hori Y, Terano H et al (1996) New antitumor substances, FR901463, FR901464 and FR901465. II. Activities against experimental tumors in mice and mechanism of action. J Antibiot (Tokyo) 49:1204–1211. doi:10.7164/antibiotics.49.1204
Ngo JCK, Chakrabarti S, Ding JH et al (2005) Interplay between SRPK and Clk/Sty kinases in phosphorylation of the splicing factor ASF/SF2 is regulated by a docking motif in ASF/SF2. Mol Cell 20:77–89. doi:10.1016/j.molcel.2005.08.025
Noguchi T, Inoue H, Tanaka T (1986) The M1- and M2-type isozymes of rat pyruvate kinase are produced from the same gene by alternative RNA splicing. J Biol Chem 261:13807–13812
Obeng EA, Chappell RJ, Seiler M et al (2016) Physiologic expression of Sf3b1K700E causes impaired erythropoiesis, aberrant splicing, and sensitivity to therapeutic spliceosome modulation. Cancer Cell 30:404–417. doi:10.1016/j.ccell.2016.08.006
Ohe K, Hagiwara M (2015) Modulation of alternative splicing with chemical compounds in new therapeutics for human diseases. ACS Chem Biol 10:914–924. doi:10.1021/cb500697f
Pan Q, Shai O, Lee LJ et al (2008) Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet 40:1413–1415. doi:10.1038/ng.259
Panasyuk G, Nemazanyy I, Zhyvoloup A et al (2009) mTORbeta splicing isoform promotes cell proliferation and tumorigenesis. J Biol Chem 284:30807–30814. doi:10.1074/jbc.M109.056085
Patra KC, Hay N (2014) The pentose phosphate pathway and cancer. Trends Biochem Sci 39:347–354. doi:10.1016/j.tibs.2014.06.005
Pavlova NN, Thompson CB (2016) The emerging hallmarks of cancer metabolism. Cell Metab 23:27–47. doi:10.1016/j.cmet.2015.12.006
Polakis P (2012) Wnt signaling in cancer. Cold Spring Harb Perspect Biol 4:9. doi:10.1101/cshperspect.a008052
Popescu N (2012) Role of DLC1 tumor suppressor gene and MYC oncogene in pathogenesis of human hepatocellular carcinoma: potential prospects for combined targeted therapeutics (Review). Int J Oncol 41:393–406. doi:10.3892/ijo.2012.1474
Poulikakos PI, Persaud Y, Janakiraman M et al (2011) RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480:387–390. doi:10.1038/nature10662
Rathmell JC, Fox CJ, Plas DR et al (2003) Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival. Mol Cell Biol 23:7315–7328. doi:10.1128/MCB.23.20.7315-7328.2003
Rauch J, Moran-Jones K, Albrecht V et al (2011) c-Myc regulates RNA splicing of the A-Raf kinase and its activation of the ERK pathway. Cancer Res 71:4664–4674. doi:10.1158/0008-5472.CAN-10-4447
Redis RS, Vela LE, Lu W et al (2016) Allele-specific reprogramming of cancer metabolism by the long non-coding RNA CCAT2. Mol Cell 61:520–534. doi:10.1016/j.molcel.2016.01.015
Riedl CC, Akhurst T, Larson S et al (2007) 18F-FDG PET scanning correlates with tissue markers of poor prognosis and predicts mortality for patients after liver resection for colorectal metastases. J Nucl Med 48:771–775. doi:10.2967/jnumed.106.037291
Röhrig F, Schulze A (2016) The multifaceted roles of fatty acid synthesis in cancer. Nat Rev Cancer 16:732–749. doi:10.1038/nrc.2016.89
Roybal GA, Jurica MS (2010) Spliceostatin A inhibits spliceosome assembly subsequent to prespliceosome formation. Nucleic Acids Res 38:6664–6672. doi:10.1093/nar/gkq494
Rubin AL (1990) Suppression of transformation by and growth adaptation to low concentrations of glutamine in NIH-3T3 Cells. Cancer Res 50:2832–2839
Sakai Y, Yoshida T, Ochiai K et al (2002) GEX1 compounds, novel antitumor antibiotics related to herboxidiene, produced by Streptomyces sp. I. Taxonomy, production, isolation, physicochemical properties and biological activities. J Antibiot (Tokyo) 55:855–862. doi:10.7164/antibiotics.55.855
Sakai T, Asai N, Okuda A et al (2004) Pladienolides, new substances from culture of Streptomyces platensis Mer-11107. II. Physico-chemical properties and structure elucidation. J Antibiot (Tokyo) 57:180–187. doi:10.7164/antibiotics.57.180
Sandberg R, Neilson JR, Sarma A et al (2008) Proliferating cells express mRNAs with shortened 3′ untranslated regions and fewer MicroRNA target sites. Science 320:1643–1647. doi:10.1126/science.1155390
Sanford JR, Gray NK, Beckmann K, Cáceres JF (2004) A novel role for shuttling SR proteins in mRNA translation. Genes Dev 18:755–768. doi:10.1101/gad.286404
Sanz DJ, Acedo A, Infante M et al (2010) A high proportion of DNA variants of BRCA1 and BRCA2 is associated with aberrant splicing in breast/ovarian cancer patients. Clin Cancer Res 16:1957–1967. doi:10.1158/1078-0432.CCR-09-2564
Schulze A, Harris AL (2012) How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature 491:364–373. doi:10.1038/nature11706
Scotti MM, Swanson MS (2016) RNA mis-splicing in disease. Nat Rev Genet 17:19–32. doi:10.1038/nrg.2015.3
Shapiro RA, Farrell L, Srinivasan M, Curthoys NP (1991) Isolation, characterization, and in vitro expression of a cDNA that encodes the kidney isoenzyme of the mitochondrial glutaminase. J Biol Chem 266:18792–18796
Shilo A, Siegfried Z, Karni R (2015) The role of splicing factors in deregulation of alternative splicing during oncogenesis and tumor progression. Mol Cell Oncol 2:e970955. doi:10.4161/23723548.2014.970955
Shimobayashi M, Hall MN (2014) Making new contacts: the mTOR network in metabolism and signalling crosstalk. Nat Rev Mol Cell Biol 15:155–162. doi:10.1038/nrm3757
Shirai CL, Ley JN, White BS et al (2015) Mutant U2AF1 expression alters hematopoiesis and pre-mRNA splicing in vivo. Cancer Cell 27:631–643. doi:10.1016/j.ccell.2015.04.008
Siegfried Z, Bonomi S, Ghigna C, Karni R (2013) Regulation of the Ras-MAPK and PI3K-mTOR signalling pathways by alternative splicing in cancer. Int J Cell Biol 2013:1–9. doi:10.1155/2013/568931
Siqueira RP, de Barbosa ÉAA, Polêto MD et al (2015) Potential antileukemia effect and structural analyses of SRPK Inhibition by N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl)isonicotinamide (SRPIN340). PLoS ONE 10:e0134882. doi:10.1371/journal.pone.0134882
Son J, Lyssiotis CA, Ying H et al (2013) Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 496:101–105. doi:10.1038/nature12040
Stark M, Wichman C, Avivi I, Assaraf YG (2009) Aberrant splicing of folylpolyglutamate synthetase as a novel mechanism of antifolate resistance in leukemia. Blood 113:4362–4369. doi:10.1182/blood-2008-08-173799
Stine ZE, Dang CV (2015) Splicing and dicing MYC-mediated synthetic lethality. Cancer Cell 28:405–406. doi:10.1016/j.ccell.2015.09.016
Stumvoll M, Perriello G, Meyer C, Gerich J (1999) Role of glutamine in human carbohydrate metabolism in kidney and other tissues. Kidney Int 55:778–792. doi:10.1046/j.1523-1755.1999.055003778.x
Sugawa N, Ekstrand AJ, James CD, Collins VP (1990) Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci 87:8602–8606. doi:10.1073/pnas.87.21.8602
Sultana N, Dienes B, Benedetti A et al (2016) Restricting calcium currents is required for correct fiber type specification in skeletal muscle. Development 143:1547–1559. doi:10.1242/dev.129676
Szeliga M, Sidoryk M, Matyja E et al (2005) Lack of expression of the liver-type glutaminase (LGA) mRNA in human malignant gliomas. Neurosci Lett 374:171–173. doi:10.1016/j.neulet.2004.10.051
Szeliga M, Matyja E, Obara M et al (2008) Relative expression of mRNAS coding for glutaminase isoforms in CNS tissues and CNS tumors. Neurochem Res 33:808–813. doi:10.1007/s11064-007-9507-6
Takenaka M, Yamada K, Lu T et al (1996) Alternative splicing of the pyruvate kinase M gene in a minigene system. Eur J Biochem 235:366–371
Tazi J, Bakkour N, Stamm S (2009) Alternative splicing and disease. Biochim Biophys Acta Mol Basis Dis 1792:14–26. doi:10.1016/j.bbadis.2008.09.017
Tiran Z, Oren A, Hermesh C et al (2008) A novel recombinant soluble splice variant of met is a potent antagonist of the hepatocyte growth factor/scatter factor-met pathway. Clin Cancer Res 14:4612–4621. doi:10.1158/1078-0432.CCR-08-0108
Traunmüller L, Gomez AM, Nguyen T-M, Scheiffele P (2016) Control of neuronal synapse specification by a highly dedicated alternative splicing program. Science 352:982–986. doi:10.1126/science.aaf2397
Turner A, McGivan JD (2003) Glutaminase isoform expression in cell lines derived from human colorectal adenomas and carcinomas. Biochem J 370:403–408. doi:10.1042/BJ20021360
Vander Heiden MG (2011) Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov 10:671–684. doi:10.1038/nrd3504
Venables JP (2004) Aberrant and alternative splicing in cancer. Cancer Res 64:7647–7654
Vicens Q, Westhof E (2014) Biogenesis of circular RNAs. Cell 159:13–14. doi:10.1016/j.cell.2014.09.005
Vogelstein B, Kinzler K (2004) Cancer genes and the pathways they control. Nat Med 10:789–799. doi:10.1038/nm1087
Vorlová S, Rocco G, LeFave CV et al (2011) Induction of antagonistic soluble decoy receptor tyrosine kinases by intronic PolyA activation. Mol Cell 43:927–939. doi:10.1016/j.molcel.2011.08.009
Wang G-S, Cooper TA (2007) Splicing in disease: disruption of the splicing code and the decoding machinery. Nat Rev Genet 8:749–761. doi:10.1038/nrg2164
Wang ET, Sandberg R, Luo S et al (2008) Alternative isoform regulation in human tissue transcriptomes. Nature 456:470–476. doi:10.1038/nature07509
Wang JB, Erickson JW, Fuji R et al (2010) Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell 18:207–219. doi:10.1016/j.ccr.2010.08.009
Wang H, Zhou M, Shi B et al (2011) Identification of an exon 4-deletion variant of epidermal growth factor receptor with increased metastasis-promoting capacity. Neoplasia 13:461–471. doi:10.1593/neo.101744
Wang Z, Jeon HY, Rigo F et al (2012) Manipulation of PK-M mutually exclusive alternative splicing by antisense oligonucleotides. Open Biol 2:120133. doi:10.1098/rsob.120133
Wang Y-H, Israelsen WJ, Lee D et al (2014) Cell-state-specific metabolic dependency in hematopoiesis and leukemogenesis. Cell 158:1309–1323. doi:10.1016/j.cell.2014.07.048
Wang Y, Mo Y, Gong Z et al (2017) Circular RNAs in human cancer. Mol Cancer 16:25. doi:10.1186/s12943-017-0598-7
Warburg O (1956) On the origin of cancer cells. Science 123:309–314. doi:10.1126/science.123.3191.309
Warburg O, Wind F, Negelein E (1927) The metabolism of tumors in the body. J Gen Physiol 8:519–530. doi:10.1097/00000441-193107000-00022
Ward PS, Thompson CB (2012) Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 21:297–308. doi:10.1016/j.ccr.2012.02.014
Ward PS, Patel J, Wise DR et al (2010) The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17:225–234. doi:10.1016/j.ccr.2010.01.020
Welbourne T (1979) Ammonia production and glutamine incorporation into glutathione in the functioning rat kidney. Can J Biochem 53:233–237
Wojtuszkiewicz A, Raz S, Stark M et al (2016) Folylpolyglutamate synthetase splicing alterations in acute lymphoblastic leukemia are provoked by methotrexate and other chemotherapeutics and mediate chemoresistance. Int J Cancer 138:1645–1656. doi:10.1002/ijc.29919
Xu CF, Chambers JA, Nicolai H et al (1997) Mutations and alternative splicing of the BRCA1 gene in UK breast/ovarian cancer families. Genes Chromosomes Cancer 18:102–110. doi:10.1002/(SICI)1098-2264(199702)18:2<102:AID-GCC4>3.0.CO;2-6
Xu Q, Modrek B, Lee C (2002) Genome-wide detection of tissue-specific alternative splicing in the human transcriptome. Nucleic Acids Res 30:3754–3766. doi:10.1093/nar/gkf492
Xu Y, Gao XD, Lee J-H et al (2014) Cell type-restricted activity of hnRNPM promotes breast cancer metastasis via regulating alternative splicing. Genes Dev 28:1191–1203. doi:10.1101/gad.241968.114
Yang M, Vousden KH (2016) Serine and one-carbon metabolism in cancer. Nat Rev Cancer 16:650–662. doi:10.1038/nrc.2016.81
Yang W, Xia Y, Ji H et al (2011) Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation. Nature 478:118–122. doi:10.1038/nature10598
Ye J, Mancuso A, Tong X et al (2012) Pyruvate kinase M2 promotes de novo serine synthesis to sustain mTORC1 activity and cell proliferation. Proc Natl Acad Sci 109:6904–6909. doi:10.1073/pnas.1204176109
Yoshida K, Sanada M, Shiraishi Y et al (2011) Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 478:64–69. doi:10.1038/nature10496
Yu X, Chini CCS, He M et al (2003) The BRCT domain is a phospho-protein binding domain. Science 302:639–642. doi:10.1126/science.1088753
Yuan TL, Cantley LC (2008) PI3K pathway alterations in cancer: variations on a theme. Oncogene 27:5497–5510. doi:10.1038/onc.2008.245
Yuneva M, Zamboni N, Oefner P et al (2007) Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells. J Cell Biol 178:93–105. doi:10.1083/jcb.200703099
Zamora-León SP, Golde DW, Concha II et al (1996) Expression of the fructose transporter GLUT5 in human breast cancer. Proc Natl Acad Sci 93:1847–1852. doi:10.1073/pnas.93.5.1847
Zhang Z, Krainer AR (2004) Involvement of SR proteins in mRNA surveillance. Mol Cell 16:597–607. doi:10.1016/j.molcel.2004.10.031
Zhang S, Wei JS, Li SQ et al (2016) MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma. Cancer Lett 371:214–224. doi:10.1016/j.canlet.2015.11.045
Zhou Z, Qiu J, Liu W et al (2012) The Akt-SRPK-SR axis constitutes a major pathway in transducing EGF signaling to regulate alternative splicing in the nucleus. Mol Cell 47:422–433. doi:10.1016/j.molcel.2012.05.014
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
On behalf of all authors, the corresponding author states that there is no conflict of interest.
Rights and permissions
About this article
Cite this article
Kozlovski, I., Siegfried, Z., Amar-Schwartz, A. et al. The role of RNA alternative splicing in regulating cancer metabolism. Hum Genet 136, 1113–1127 (2017). https://doi.org/10.1007/s00439-017-1803-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00439-017-1803-x